Modality
Degrader
MOA
SGLT2i
Target
CDK4/6
Pathway
PD-1/PD-L1
ADPKDHNSCCNMOSD
Development Pipeline
Preclinical
Dec 2020
→ Aug 2027
PreclinicalCurrent
NCT08250767
1,129 pts·ADPKD
2020-12→2027-08·Completed
1,129 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-211.4y awayInterim· ADPKD
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2027-08-21 · 1.4y away
ADPKD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08250767 | Preclinical | ADPKD | Completed | 1129 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |